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Abstract
Muscular dystrophy and peripheral neuropathy have been linked to mutations in genes encoding
nuclear envelope proteins; however, the molecular mechanisms underlying these disorders remain
unresolved. Nuclear envelope protein p19A is a protein of unknown function encoded by a gene at
chromosome 4q35. p19A levels are significantly reduced in human muscle as cells differentiate from
myoblasts to myotubes; however, its levels are not similarly reduced in all differentiation systems
tested. Because 4q35 has been linked to facioscapulohumeral muscular dystrophy (FSHD) and some
adjacent genes are reportedly misregulated in the disorder, levels of p19A were analyzed in muscle
samples from patients with FSHD. Although p19A was increased in most cases, an absolute
correlation was not observed. Nonetheless, p19A downregulation in normal muscle differentiation
suggests that in the cases where its gene is inappropriately reactivated it could affect muscle
differentiation and contribute to disease pathology.
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Introduction
The nuclear envelope (NE) is a complex subdomain of the nucleus that is linked to multiple
diseases including those affecting striated muscle. Mutations in LMNA, which encodes A-type
lamins, cause several disorders characterized by dilated cardiomyopathy with variable skeletal
muscle involvement, including Emery-Dreifuss muscular dystrophy (EDMD) and limb-girdle
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muscular dystrophy type 1B (LGMD1B) [1;2;3;4]. Mutations in EMD encoding emerin cause
X-linked EDMD [5]. The molecular mechanisms by which mutations in genes encoding NE
proteins produce pathology in striated muscle remain unclear, but potential causes that are
supported experimentally include mechanical instability of the nucleus, altered gene
expression, disruption of cell signaling cascades, and failure of satellite cell function [4;6].
This wide range of affected functions suggests that additional interacting NE proteins are
involved in developing disease pathologies and implies that such partner proteins could be
involved in additional muscle disorders.
Partner proteins could be among 67 previously uncharacterized nuclear membrane proteins
identified by proteomics [7]. The human homolog of one of these proteins, p19A (initially
called NET19), is encoded in the q35 region of chromosome 4 that is linked to
fascioscapulohumeral muscular dystrophy (FSHD), one of the most common hereditary
myopathies that has some clinical features similar to the NE-linked limb-girdle muscular
dystrophy (type 1B), beginning with facial muscle degeneration but progressing to limb-girdle
muscles and deltoids [3;8]. FSHD is not associated with point mutations in any specific gene:
rather, over >90% of cases correlate with a reduced number of D4Z4 repeats at 4q35. Wild-
type alleles of some 4q35 genes are upregulated in the disease, though the molecular
mechanism remains unresolved [9;10;11]. As p19A is located in 4q35 we considered that its
misregulation might contribute to FSHD pathology. p19A levels were higher in some patients,
but a clear correlation could not be made due to high variation among both control and patient
samples. Strikingly, p19A protein levels are greatly reduced during muscle differentiation and
absent from or expressed at low levels in adult muscle. Thus in those patients in which it is
upregulated, p19A could contribute to muscle pathology.
Materials and methods
Original Predicted NET19 Exons
Amino acid sequences predicted from each exon of the original orf XP_298567.
1:MKLELRVPVVLDVFTEMATLLTIITRLVNKWVDLWPRQENG
2:FILVSSWLTFLFSPGTLSVAMFCDTKWKTENIDLQLERRMEQR
3:CSMFLAVESTRTSAVVQEKPAGQGLCVRTAQWAVWSRFALSVRPELARTCRKLL
RSSGGA
4:GHLRGSLASFRSRIELRRQIARPHAAGRETCCPLRRNHAGAPRLPSACSPEEVPVSR
VLMRGLKRKRGRRARDPKGRGGEEETLALSFSCQQWQPPPQ
Antibody Generation
Peptides (3.5 mg each) representing four regions in the XP_298567 coding sequence (a =
TRLVNKWVDLWPRQENGF, b = DTKWKTENIDLQLERRME, c =
NHAGAPRLPSACSPEEVP, and d = LKRKRGRRARDPKGRGGE) were conjugated to
keyhole limpet hemocyanin (KLH; 7 mg) with sulfo-SMCC (Pierce Chemical Co.; 1 mg). Free
crosslinker was removed on a PD10 column (Pharmacia) and 500 μg of complexed peptide
was emulsified with TiterMax Classic Adjuvant (Sigma) for injection 1 and Freund’s
incomplete adjuvant (Sigma) for subsequent injections (3-week intervals) into New Zealand
White rabbits. Actin antibodies (A-1978 Sigma) and lamin A (2962) and B1 (3931) antibodies
[12] were previously described.
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Cell Culture and Differentiation
All non-differentiation media contained 10% fetal calf serum, 100 μg/ml penicillin and 100
μg/ml streptomycin sulfate (Invitrogen). This was added to high glucose DMEM (Invitrogen)
for HT1080, HeLa, COS-7, 293T and C2C12 cells, DMEM with MEM non-essential amino
acids (Gibco) and 1 mM Na-Pyruvate (Gibco) for 3T3-L1 cells, RPMI (Gibco) for HL-60 and
EL-4 cells, and SKGM (Cambrex, CC-3160) for primary myoblasts.
Myoblasts were isolated from patient and control samples using approved protocols and ethics
considerations. Cultures were split and half was cultured in 2% horse serum medium for 6–9
days to differentiate into myotubes. Confluent C2C12 cells were differentiated in DMEM
containing 0.1 % FCS, Na-pyruvate, 5 μg/ml insulin and 5 μg/ml transferrin. Two days post-
confluent 3T3-L1 cells were differentiated with medium containing 1 μM dexamethasone, 0.5
mM 3-isobutyl-1-methylxanthine (IBMX), and 10 μg/ml insulin that was replaced after 2 days.
At 4 days fresh medium containing just insulin was added. HL-60 cells (ATCC) were
differentiated like macrophages with 10 nM TPA (phorbol 13 myristate acetate; Calbiochem)
or like granulocytes with 1 μM trans-retinoic acid (Sigma).
For cell doubling measurements daily averages of at least 5 haemocytometer counts for
suspension cultures and 20 grids on CELLocate coverslips (Eppendorf) were used to plot the
number of cell divisions per unit time.
Subcellular Fractionation
Rat liver NEs and microsomes were isolated as previously detailed [13]. For salt extractions,
6 × 107 NEs were resuspended in 500 mM NaCl, 25 mM Tris pH 8.0, incubated on ice 15 min,
and then centrifuged at 10,000 × g for 30 min to separate supernatant and pellet fractions. For
alkali extractions, the NEs or microsomes were instead resuspended in 0.1 N NaOH, 0.01 M
DTT and immediately centrifuged at 50,000 × g for 30 min. An equivalent percentage of
supernatant and pellet were loaded onto gels.
Western Blotting
PVDF membranes were blocked in 10% milk, incubated with primary antibodies for 1 h,
washed with 0.2% Tween-20, and incubated with anti-rabbit IgG-HRP 25 min followed by
further washes. Membranes were then incubated in ECL (Pierce) 5 min and exposed to Biomax
Light autoradiography film (Kodak).
Results and discussion
A protein initially termed NET19 was identified by tandem mass spectrometry of a complex
peptide mixture generated from a NE fraction [7]. Fragmentation spectra of the peptide yielded
a high confidence match to the translated sequence (XP_298567) of hypothetical orf
(XM_298567) located at 4q35 in the human genome encoding a 242 amino acid protein. This
database entry was subsequently removed as several different contig assemblies rendered the
precise sequence uncertain, presumably related to its proximity to the D4Z4 repeat sequences
at 4q35. To test the validity of the original mass spectrometry identification four peptide
antibodies were generated based on three of the four exons of the original annotated sequence
that spanned roughly 40 Kb (Fig. 1A, B), all of which remained in the genomic sequence for
4q35 (AC093909, Homo sapiens BAC clone RP11-756P1). Antibodies to peptides from exons
1 and 2, 30 kb distant from one another, both recognized a 70 kDa band on Western blots of
HeLa cells and rat liver NEs (Fig. 1C, left). In contrast, both antibodies to exon 4 peptides
recognized a prominent 50 kDa protein in HeLa lysates, which was not clearly evident in rat
liver NEs (Fig. 1C, right). Thus, the original predicted exons 1 and 2 encode parts of a 70 kDa
protein, which we refer to as p19A, although they only account for 14% of its mass. Several
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attempts to amplify a fragment of p19A cDNA by PCR from a human liver cDNA library using
various hypothetical exon combinations based on splice junction prediction algorithms were
unsuccessful, so the complete sequence remains unknown. The original predicted exon 4
encodes part of a second 50 kDa protein, which we refer to as p19B.
The two proteins had very distinctive properties when tested for subcellular
compartmentalization and membrane insertion. The p19A antibodies reacted with a NE
fraction, but did not react with a microsome fraction on Western blots (Fig. 2A). In contrast
the p19B antibodies reacted with a protein in the microsomes and failed to react with NEs.
Thus, only p19A can be classified as a NE protein. Each confirmed p19A exon has a strongly
predicted transmembrane segment by TMHMM version 2.0 [14]. To further characterize p19A
membrane association, NEs were extracted with either 500 mM NaCl or 0.1 N NaOH and
probed by Western blot with antibodies. LAP2β served as control, being a well-characterized
integral nuclear membrane protein. Both p19A and LAP2β strongly resisted extraction with
500 mM salt; however almost no LAP2β was released from NEs with the alkali treatment,
while most of the p19A was solubilized (Fig. 2B). The weaker membrane association is not
inconsistent with membrane insertion as other NE transmembrane proteins have quite varied
extraction properties [15;16], but p19A might also be inserted as a “monotypic” protein that
does not span the two bilayers.
As p19A and p19B are located in a chromosomal region linked to FSHD, we tested if, like
some other genes at 4q35 [9;10;11], they are upregulated in FSHD patients. Myoblasts were
isolated from four patient samples and controls that were coded so that analysis would be
unbiased. All patients had <28 kb EcoRI fragments of the D4Z4 repeats, consistent with FSHD
linked to reduced repeat number. Equivalent sample loading was based on Coomassie blue
staining and confirmed by staining for actin and lamins. The p19A level was higher in three
of the four patient samples than in all four controls and much higher than three controls (Fig.
3A). The p19A level in the fourth patient sample was still stronger than half of the controls.
Thus, though upregulation of p19A could not be absolutely correlated with FSHD, correlation
could be masked by the variable expression in both disease and control samples.
To understand the extent of this variability, protein lysates from adult human muscle of FSHD
patients and controls were probed for p19A. No p19A band was detectable in any of these
samples, though it was readily detectable in Hela cell lysate loaded on the same gel (Fig. 3B,
left). Furthermore, lamin protein was readily detectable in the muscle samples (Fig. 3B, right);
so p19A should have been detectable if present. The absence of p19A in adult muscle and
variable levels observed in isolated myoblasts suggested that p19A levels might be reduced in
muscle differentiation. To test this hypothesis, myoblasts isolated from patient samples and
controls were induced to differentiate into myotubes by serum withdrawal, similar amounts of
total protein were run on gels, and p19A was detected by immunoblotting (Fig. 3C). In every
instance, regardless of the variable starting levels, the levels of p19A dropped precipitously
upon differentiation. In contrast p19B levels were essentially unchanged.
One possible explanation for the variability in basal levels of p19A in myoblasts was suggested
by the observation that those with lower levels took much longer to double than those with
higher levels. To test if higher p19A protein levels correlate to a faster cell doubling time,
protein lysates from a variety of cell lines with different doubling times were compared for
levels of p19A, p19B, and lamin B1 (Fig. 4A). However, in contrast to primary myoblasts,
immortalized cell lines with shorter doubling times did not have higher levels of p19A. 293T
and EL-4 cells, which had respective doubling times of 11 and 14 h, had very low p19A levels.
In contrast, HT1080, HeLa, COS7, and 3T3-L1 cells which all doubled at >20 h expressed
high levels of p19A (Fig. 4A, B). Levels were also high in C2C12 cells (doubling time, 19 h).
In contrast, levels of p19B were similar in all lines except the suspension EL-4 cells.
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To test if p19A loss is a general characteristic of cellular differentiation, p19A levels were also
measured in four in vitro differentiation systems: muscle (C2C12), adipocyte (3T3-L1),
macrophage-like (HL-60), and granulocyte-like (HL-60). Levels of p19A dropped below the
level of detection during C2C12 differentiation and to very low levels during 3T3-L1
differentiation (Fig. 4B). As serum is not reduced in 3T3-L1 differentiation, the loss of p19A
is not related to serum withdrawal employed to differentiate myoblasts to myotubes. Another
variable is introduced with HL-60 cells, which in contrast to the other lines are grown in
suspension. When treated with retinoic acid, they withdraw from the cell cycle and differentiate
along a granulocytic pathway while remaining in suspension [17]. When treated with phorbol
esters, they adhere to a substratum and spread as they acquire macrophage-like characteristics
[17]. The levels of p19A were maintained during the granulocytic differentiation (Fig. 4C, dg),
while they were dramatically reduced during the macrophage-like differentiation (Fig. 4C,
dm). As cells in both differentiation paradigms withdraw from the cell cycle, the loss of p19A
in just the macrophage-like differentiation appears to be unrelated to withdrawal from the cell
cycle. The only shared characteristic of all differentiation systems in which p19A was lost is
that the cells underwent significant morphological changes (myoblast fusion, fat deposition,
substratum adherence and spreading).
This suggests that p19A may be involved in a nuclear function that must be removed to enable
tissue remodeling. The morphological changes in these differentiation systems would require
repositioning of nuclei and restructuring of nucleo-cytoskeletal connections as overall cell
shape changes. As p19A was most completely lost in muscle differentiation it is tempting to
speculate that failure to remove p19A might prevent satellite cells from differentiating to
replace damaged muscle. Such an effect could contribute to the pathophysiology of FSHD in
the patients who exhibited upregulation of p19A.
The mechanism underlying the pathophysiology of FSHD remains contentious, but it is
generally agreed that loss of D4Z4 repeats and consequent changes in the epigenetic makeup
of the surrounding region are significant factors, likely affecting the expression of multiple
genes [18]. Until the complete p19A gene can be cloned it will not be possible to form a detailed
molecular model for how it might contribute to FSHD or other disorders. However, it is
intriguing that this is the first 4q35-encoded protein in NEs. A potential link between FSHD
and the NE came from observations that the 4q telomere occurs preferentially at the nuclear
periphery [19] and is associated with peripheral heterochromatin [20]. This finding is
interesting in relation to the idea of a position effect in FSHD; however, the position effect
might relate to proximity to the epigenetically silent environment of the NE [21;22] if a
threshold number of D4Z4 repeats is required for NE tethering. NE tethering of 4q35 might
also explain why only reduction in D4Z4 repeats at 4q35 causes FSHD while reduction in other
D4Z4 repeats at 10q26 has no disease correlation [23].
The considerable clinical variability of both FSHD and the laminopathies LGMD1B and
EDMD is consistent with the high degree of variability in expression levels for p19A observed
here. Thus whatever the precise role of p19A in cellular/tissue remodeling and 4q tethering to
the periphery, p19A is a reasonable candidate to influence the pathology of FSHD or muscle
laminopathies if inappropriately expressed in adult cells.
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Fig. 1.
The original NET19 hypothetical orf encompasses two different proteins. (A) NET19 genomic
structure. 4q35 expansion showing scaled locations of several genes/motifs suggested to be
involved in FSHD: ANT1 (x), FRG1 (y), FRG2 (z), D4Z4 repeats (d4), telomere (t), and
position of NET19, 273 kb upstream of FRG1 and 2 Mb upstream of the D4Z4 repeats. Further
expansion of NET19 exons (crossbars, 10 kb). Exon 1 starts at 191,185,000 on chromosome
4 and roughly 30 kb spans between predicted exons 1 and 2. (B) Peptides used to generate
antibodies: a in exon 1, b in exon 2, and c and d in exon 4. (C) These antibodies were used to
detect proteins in HeLa cells and rat liver NEs (RLNE). Antibodies to peptides a and b both
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recognize the same 65–70 kDa band subsequently referred to as p19A, while antibodies c and
d both recognize a distinct ~50 kDa protein subsequently referred to as p19B.
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Fig. 2.
p19A and p19B have different subcellular localizations. (A) Equal concentrations of rat liver
NEs (NE) and microsomes (MM) were probed with antibodies to p19A (a, b) and p19B (c, d).
Both p19A antibodies reacted only with NEs while both p19B antibodies reacted only with
microsomes. (B) NEs extracted with 500 mM NaCl or 0.1 N NaOH. After salt or alkali
treatment insoluble material was pelleted and an equal percentage of supernatant (s) and pellet
(p) was analyzed by Western blot with LAP2β and p19A antibodies. Both LAP2β and p19A
resisted salt extraction, remaining fully in the pellet. In contrast, almost no LAP2β was
extracted with alkali treatment while most p19A was extracted.
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Fig. 3.
Protein levels of p19A are variable in primary human myoblasts and elevated levels cannot be
clearly correlated with FSHD. (A) Myoblast lines from four FSHD patients (p) and controls
(c) were tested for levels of p19A. In general, levels were increased in patients, but the
correlation was not absolute. (B) Antibodies to p19A (left) failed to recognize the protein in
adult muscle samples (lanes 1–5) from FSHD patients and controls, though they recognized
the protein in a HeLa extract (h) on the same gel. The same samples were run on a separate gel
and reacted with antibodies to A/C lamins (right), confirming sufficient protein was loaded in
the lanes to detect p19A if present. Lane 1 clinically diagnosed with Biliary cirrhosis and
muscle biopsy “Nearly normal.” Lane 2 clinically diagnosed with Progressive supra-nuclear
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palsy and muscle biopsy “Normal.” Lanes 3 and 4 both clinically diagnosed with FSHD and
muscle biopsy “Mild myopathy.” Lane 5 clinically diagnosed with Mononeuritis multiplex
and muscle biopsy “Nearly normal.” (C) Myoblast lines from unaffected human donor (c) and
patients with FSHD (p) were cultured and differentiated in vitro. In both myoblasts from
controls and patients with FSHD, though the initial levels of p19A varied, the protein levels
were reduced during myoblast (u) to myotube (d) differentiation. h, HeLa cell extract.
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Fig. 4.
p19A disappears during differentiation in certain in vitro systems. (A) Levels of p19A are lower
in more rapidly dividing cell lines. Protein lysates from various cell lines were loaded on gels
after levels were equilibrated with Coomassie staining and reacted with antibodies to p19A,
p19B, or lamin B1. Cell doubling times were measured from the same cultures prior to making
lysates. EL-4 and 293T cells doubled in roughly half the time of the other cells and p19A levels
were also much lower. (B) Levels of p19A were reduced during C2C12 and 3T3-L1
differentiation. Protein levels were equilibrated by Coomassie staining. Levels of p19A were
reduced to undetectable levels in the differentiated C2C12 cells and to very low levels in the
differentiated 3T3-L1 cells. Levels of p19B were also reduced, unlike for human primary
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myoblast differentiation. Levels of lamin B1 were relatively unaffected by the differentiation.
(C) Levels of p19A and p19B during HL-60 differentiation. HL-60 cells were differentiated
into granulocyte-like cells (dg) or macrophage-like cells (dm) or left undifferentiated (u). An
equivalently loaded Coomassie blue stained gel shows that similar amounts of total protein are
being compared for all conditions (left). Blots were reacted with antibodies to p19A, p19B and
the nucleoporin p58 as a control (right). p19A levels were reduced when cells were
differentiated into megakaryocytes, but not when they were differentiated into granulocytes.
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